Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company that sits at the intersection of computational and experimental technologies, focused on making small molecule medicines against precision medicine targets. The company was built upon insights into protein motion and how this dynamic behavior relates to protein function, driven by its Dynamo platform, which integrates experimental and computational approaches to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic disease.

Relay Therapeutics was built upon insights into protein motion and how this dynamic behavior relates to protein function. These insights are driven by the Dynamo platform, which integrates an array of leading-edge experimental and computational approaches and enables the company to effectively drug protein targets that have previously been intractable or inadequately addressed. Three important forces led to the founding of Relay Therapeutics: genomic data, experimental resolution, and computational power and speed. The genomic revolution enabled a better understanding of the targets that drive disease and which patients may benefit from new targeted therapies. Structural biology techniques emerged that allow scientists to visualize protein motion at atomic resolutions. Technology improved to the point that molecular dynamics simulations can be run on proteins at biologically relevant timescales useful for drug discovery. Through integration, the Dynamo platform provides a differentiated understanding of protein structure and motion.

Clinical-stage precision medicine company at the intersection of computational and experimental technologies.

• 2020-07-15

  Relay Therapeutics prices IPO[4]Relay Therapeutics 为首次公开募股定价medcitynews.com

  Reported: 2020-07-16

  Relay Therapeutics priced its initial public offering at $400 million, offering 20 million shares of common stock at $20 per share. The shares were expected to begin trading on Nasdaq on Thursday, and the offering was expected to close Monday.

  Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.

1. 1Relay Therapeuticsrelaytx.com
2. 2Who We Are - Relay Therapeuticsrelaytx.com
3. 3Relay Therapeuticswikidata.org
4. 4Relay Therapeutics 为首次公开募股定价medcitynews.com